JP2024509501A - 新規活性を持つｈｈｌａ２結合剤 - Google Patents

新規活性を持つｈｈｌａ２結合剤 Download PDF

Info

Publication number
JP2024509501A
JP2024509501A JP2023544261A JP2023544261A JP2024509501A JP 2024509501 A JP2024509501 A JP 2024509501A JP 2023544261 A JP2023544261 A JP 2023544261A JP 2023544261 A JP2023544261 A JP 2023544261A JP 2024509501 A JP2024509501 A JP 2024509501A
Authority
JP
Japan
Prior art keywords
hhla2
binding
antibody
antigen
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023544261A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024509501A5 (enExample
Inventor
スコット チャッペル，
デトレフ ビニスキーウィチ，
ビジャン エテマド－ギルバートソン，
ナドタカーン ボーランド，
ネルス ニールソン，
ビアンカ プリンツ，
Original Assignee
ネクストポイント セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ネクストポイント セラピューティクス， インコーポレイテッド filed Critical ネクストポイント セラピューティクス， インコーポレイテッド
Publication of JP2024509501A publication Critical patent/JP2024509501A/ja
Publication of JP2024509501A5 publication Critical patent/JP2024509501A5/ja
Priority to JP2026078333A priority Critical patent/JP2026119212A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Catalysts (AREA)
JP2023544261A 2021-01-28 2022-01-28 新規活性を持つｈｈｌａ２結合剤 Pending JP2024509501A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026078333A JP2026119212A (ja) 2021-01-28 2026-05-07 新規活性を持つｈｈｌａ２結合剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163142832P 2021-01-28 2021-01-28
US63/142,832 2021-01-28
PCT/US2022/014423 WO2022165258A1 (en) 2021-01-28 2022-01-28 Hhla2 binding agents with novel activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026078333A Division JP2026119212A (ja) 2021-01-28 2026-05-07 新規活性を持つｈｈｌａ２結合剤

Publications (2)

Publication Number Publication Date
JP2024509501A true JP2024509501A (ja) 2024-03-04
JP2024509501A5 JP2024509501A5 (enExample) 2025-02-04

Family

ID=82652818

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023544261A Pending JP2024509501A (ja) 2021-01-28 2022-01-28 新規活性を持つｈｈｌａ２結合剤
JP2026078333A Pending JP2026119212A (ja) 2021-01-28 2026-05-07 新規活性を持つｈｈｌａ２結合剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026078333A Pending JP2026119212A (ja) 2021-01-28 2026-05-07 新規活性を持つｈｈｌａ２結合剤

Country Status (11)

Country Link
US (1) US20250270323A1 (enExample)
EP (1) EP4284431A4 (enExample)
JP (2) JP2024509501A (enExample)
KR (1) KR20230135637A (enExample)
CN (1) CN116981476A (enExample)
AU (1) AU2022214939A1 (enExample)
BR (1) BR112023014826A2 (enExample)
CA (1) CA3207494A1 (enExample)
IL (1) IL304584A (enExample)
MX (1) MX2023008182A (enExample)
WO (1) WO2022165258A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN122161832A (zh) * 2023-09-08 2026-06-05 Nextpoint治疗公司 抗体-药物缀合物
CN119841949B (zh) * 2023-10-17 2026-06-05 科辉智药(深圳)新药研究中心有限公司 一种抗人hhla2的纳米抗体及其应用
CN121005781A (zh) * 2024-05-24 2025-11-25 合肥天港免疫药物有限公司 高亲和力b7h7抗体或其抗原结合片段及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019204057A1 (en) * 2018-04-06 2019-10-24 Dana-Farber Cancer Institute, Inc. Kir3dl3 as an hhla2 receptor, anti-hhla2 antibodies, and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015167948A1 (en) * 2014-04-30 2015-11-05 Albert Einstein College Of Medicine Of Yeshiva University Tmigd2 and its derivatives as blockers or binders of cancer-expressed hhla2 for immunotherapies
TWI917306B (zh) * 2017-07-06 2026-03-11 荷蘭商米樂斯股份有限公司 藉由細胞表現之調控生物活性的結合分子
CN111196852A (zh) * 2018-11-16 2020-05-26 四川科伦博泰生物医药股份有限公司 抗tigit抗体及其用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019204057A1 (en) * 2018-04-06 2019-10-24 Dana-Farber Cancer Institute, Inc. Kir3dl3 as an hhla2 receptor, anti-hhla2 antibodies, and uses thereof

Also Published As

Publication number Publication date
KR20230135637A (ko) 2023-09-25
WO2022165258A1 (en) 2022-08-04
BR112023014826A2 (pt) 2023-10-03
EP4284431A4 (en) 2025-01-15
IL304584A (en) 2023-09-01
EP4284431A1 (en) 2023-12-06
JP2026119212A (ja) 2026-07-16
US20250270323A1 (en) 2025-08-28
CN116981476A (zh) 2023-10-31
CA3207494A1 (en) 2022-08-04
AU2022214939A1 (en) 2023-07-20
MX2023008182A (es) 2023-09-15

Similar Documents

Publication Publication Date Title
JP7708741B2 (ja) Ｈｅｒ３抗原結合性分子を使用したがんの処置および予防
JP7153626B2 (ja) 抗ヒト４－１ｂｂ抗体およびその使用
TWI825086B (zh) Her3抗原結合分子
CN109071666B (zh) 人脊髓灰质炎病毒受体(pvr)特异性抗体
US9403906B2 (en) Method of treatment of a solid tumor with interleukin-1 accessory protein antibody
JP2023541473A (ja) 抗４－１ｂｂ－抗ｐｄ－ｌ１二重特異性抗体、ならびにその医薬組成物および使用
CN121021694A (zh) 结合cd123的多肽及其用途
JP2018532383A (ja) ヒトｔ細胞免疫グロブリン及びｉｔｉｍドメイン（ｔｉｇｉｔ）に特異的な抗体
CN115210261B (zh) 抗半乳糖凝集素-9抗体及其用途
US20250270323A1 (en) Hhla2 binding agents with novel activity
EP3882271A2 (en) Ifn-gamma-inducible regulatory t cell convertible anti-cancer (irtca) antibody and uses thereof
JP2023541853A (ja) Ｐｄ－１ポリペプチド変異体
CN117279954A (zh) 抗人cxcr5抗体及其用途
HK40102688A (en) Hhla2 binding agents with novel activity
JP2022554270A (ja) 抗ｐｄ－１抗体による癌を治療する方法
US20250171533A1 (en) Kir3dl3 inhibitors and immune cell activating agents
US20250138018A1 (en) T cell and nk cell engagers
WO2025175056A1 (en) Multispecific antibodies or antigen binding fragments thereof to b7-h7 and immune effector cell antigens
HK40118068A (en) Kir3dl3 inhibitors and immune cell activating agents
HK40052624B (en) Treatment and prevention of cancer using her3 antigen-binding molecules

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230807

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250127

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260507